SG11202001387WA - Combination therapy of lasmiditan and a cgrp antagonist for use in the treatment of migraine - Google Patents

Combination therapy of lasmiditan and a cgrp antagonist for use in the treatment of migraine

Info

Publication number
SG11202001387WA
SG11202001387WA SG11202001387WA SG11202001387WA SG11202001387WA SG 11202001387W A SG11202001387W A SG 11202001387WA SG 11202001387W A SG11202001387W A SG 11202001387WA SG 11202001387W A SG11202001387W A SG 11202001387WA SG 11202001387W A SG11202001387W A SG 11202001387WA
Authority
SG
Singapore
Prior art keywords
lasmiditan
migraine
treatment
combination therapy
cgrp antagonist
Prior art date
Application number
SG11202001387WA
Other languages
English (en)
Inventor
Sheena Aurora
Kirk Willis Johnson
John Henry Krege
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SG11202001387WA publication Critical patent/SG11202001387WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202001387WA 2017-09-06 2018-08-30 Combination therapy of lasmiditan and a cgrp antagonist for use in the treatment of migraine SG11202001387WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762554726P 2017-09-06 2017-09-06
PCT/US2018/048730 WO2019050759A1 (en) 2017-09-06 2018-08-30 POLYTHERAPY OF LASMIDITAN AND CGRP ANTAGONIST FOR USE IN THE TREATMENT OF MIGRAINE

Publications (1)

Publication Number Publication Date
SG11202001387WA true SG11202001387WA (en) 2020-03-30

Family

ID=63529021

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202001387WA SG11202001387WA (en) 2017-09-06 2018-08-30 Combination therapy of lasmiditan and a cgrp antagonist for use in the treatment of migraine

Country Status (17)

Country Link
US (1) US20200268735A1 (https=)
EP (2) EP3678665A1 (https=)
JP (5) JP6922092B2 (https=)
KR (3) KR20230025945A (https=)
CN (3) CN116059204A (https=)
AU (1) AU2018329568B2 (https=)
BR (1) BR112020002077A2 (https=)
CA (1) CA3073996C (https=)
EA (1) EA202090457A1 (https=)
IL (2) IL314347A (https=)
MA (2) MA50073A (https=)
MX (2) MX2020002554A (https=)
MY (1) MY205182A (https=)
SG (1) SG11202001387WA (https=)
TW (1) TWI754772B (https=)
WO (1) WO2019050759A1 (https=)
ZA (1) ZA202000443B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2413933T5 (pl) 2009-04-02 2021-10-18 Colucid Pharmaceuticals, Inc. 2,4,6-trifluoro-N-[6-(1-metylopiperydyno-4-karbonylo)pirydyn-2-ylo]benzamid do leczenia migreny drogą doustną lub dożylną
TWI685505B (zh) * 2011-05-20 2020-02-21 美商艾爾德生物控股有限責任公司 抗降血鈣素基因相關胜肽（ａｎｔｉ-ｃｇｒｐ）組成物及其用途
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
JP6491669B2 (ja) 2014-02-05 2019-03-27 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｃｇｒｐ活性化合物の錠剤製剤
KR20190075130A (ko) 2016-12-06 2019-06-28 코루시드 파마슈티컬즈 인코포레이티드 피리디노일피페리딘 5-ht1f 작용제에 관한 조성물 및 방법
TWI754772B (zh) * 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
US20190374518A1 (en) * 2018-06-08 2019-12-12 Allergan Pharmaceuticals International Limited Treatment of migraine
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
TWI826514B (zh) 2018-09-04 2023-12-21 美商美國禮來大藥廠 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
JP2022517433A (ja) * 2019-01-20 2022-03-08 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド 突出性の片頭痛を処置するためのｃｇｒｐアンタゴニスト
TWI776175B (zh) 2019-07-09 2022-09-01 美商美國禮來大藥廠 大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體，以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備
CN116390712A (zh) 2020-07-29 2023-07-04 阿勒根制药国际有限公司 治疗偏头痛
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
WO2023049920A1 (en) 2021-09-27 2023-03-30 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine
CN116270505A (zh) * 2021-12-20 2023-06-23 南京科默生物医药有限公司 含半琥珀酸拉司米地坦的口服固体制剂及其3d打印制备技术
JP7499538B1 (ja) 2023-03-29 2024-06-14 ロゴスサイエンス株式会社 慢性疼痛の治療、改善およびセルフケアシステム

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002353D0 (sv) * 2000-06-22 2000-06-22 Astrazeneca Ab New use
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
US20050065094A1 (en) * 2003-09-05 2005-03-24 Boehringer Ingelheim International Gmbh Use of telmisartan for the prevention and treatment of vascular headache
WO2005046659A2 (en) * 2003-11-12 2005-05-26 Nps Pharmaceuticals, Inc. Migraine treatments including isovaleramide compounds and serotonin agonists
DE102004063753A1 (de) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
US8697876B2 (en) * 2010-04-02 2014-04-15 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists
AR081434A1 (es) * 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
WO2018055574A1 (en) * 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
RU2770066C2 (ru) * 2017-03-02 2022-04-14 Бет Изрейэл Диконисс Медикал Сентер, Инк. Отбор пациентов с головной болью, восприимчивых к антителам, направленным против кальцитонин ген-родственного пептида
TWI754772B (zh) * 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法

Also Published As

Publication number Publication date
JP7480261B2 (ja) 2024-05-09
KR20200036919A (ko) 2020-04-07
EP4397317A2 (en) 2024-07-10
EP3678665A1 (en) 2020-07-15
MY205182A (en) 2024-10-04
CN111032044A (zh) 2020-04-17
EP4397317A3 (en) 2024-10-16
EA202090457A1 (ru) 2020-06-10
KR20260027357A (ko) 2026-02-27
JP6922092B2 (ja) 2021-08-18
JP2023029872A (ja) 2023-03-07
JP7183355B2 (ja) 2022-12-05
US20200268735A1 (en) 2020-08-27
IL314347A (en) 2024-09-01
AU2018329568A1 (en) 2020-02-06
MA50073A (fr) 2020-07-15
JP7711255B2 (ja) 2025-07-22
TWI754772B (zh) 2022-02-11
JP2021176884A (ja) 2021-11-11
MA71474A (fr) 2025-04-30
MX2020002554A (es) 2020-07-13
CA3073996C (en) 2022-05-31
AU2018329568B2 (en) 2021-09-23
JP2020530861A (ja) 2020-10-29
WO2019050759A1 (en) 2019-03-14
JP2024109585A (ja) 2024-08-14
ZA202000443B (en) 2022-07-27
TW201919624A (zh) 2019-06-01
JP2025165940A (ja) 2025-11-05
MX2023008760A (es) 2023-08-02
KR20230025945A (ko) 2023-02-23
IL273031A (en) 2020-04-30
CA3073996A1 (en) 2019-03-14
CN116509861A (zh) 2023-08-01
BR112020002077A2 (pt) 2020-07-28
NZ761634A (en) 2024-05-31
CN116059204A (zh) 2023-05-05

Similar Documents

Publication Publication Date Title
IL273031A (en) Combined treatment of lasmiditan and a CGRP antagonist for use in the treatment of migraine
LT3806898T (lt) Gremlin-1 antagonistas, skirtas naudoti vėžio gydymui
HUE069231T2 (hu) Aprocitentán magas vérnyomás és kapcsolódó betegségek kezelésében történõ alkalmazásra, kombinációban valzartánnal
IL258500A (en) Combination therapy with glutaminase inhibitors and immuno-oncology agents
SI3331610T1 (sl) Sredstva za uporabo pri zdravljenju gliomov
GB201507721D0 (en) Immunosuppressive agents and their use in therapy
ZA201900777B (en) Usage and dosage of therapeutic agents for endometriosis
GB201604213D0 (en) Drug combination and its use in therapy
IL247586A0 (en) Use of Aribolin and mtor inhibitors as a combined treatment for cancer
GB201702160D0 (en) Inhibitors for use in therapy
ZA201905402B (en) Compounds and their use in the treatment of schistosomiasis
IL246855A0 (en) Materials for use in the treatment of retinitis
IL273863B1 (en) Hemorrhoid treatment device
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
PL3262069T3 (pl) Zastosowanie przeciwciał i antagonistów skierowanych przeciwko LRG1 w leczeniu
HUE045185T2 (hu) Új terápiás vegyület és terápiában történõ alkalmazása
IL271211B1 (en) Acetyl leucine for use in the treatment of migraine
ZA201600312B (en) Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders
IL269121A (en) Usl-311 for use in the treatment of cancer
GB201615844D0 (en) Agents for use in therapy
HK40022380A (en) Combination therapy of lasmiditan and a cgrp antagonist for use in the treatment of migraine
ZA201707603B (en) Clonidine and/or clonidine derivatives for use in the prevention of skin injury resulting from radiotherapy
HK1242990A1 (en) Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer